Heartburn, treatment in primary care: randomised, double blind study for 8 weeks

被引:82
作者
Hatlebakk, JG [1 ]
Hyggen, A
Madsen, PH
Walle, PO
Schulz, T
Mowinckel, P
Bernklev, T
Berstad, A
机构
[1] Univ Bergen, Haukeland Sykehus, Dept Med, N-5021 Bergen, Norway
[2] Astra Norge, N-1471 Skarer, Norway
[3] Lyshovden Legekontor, N-5148 Fyllingsdalen, Norway
[4] Aust Agder Cent Hosp, N-4800 Arendal, Norway
来源
BMJ-BRITISH MEDICAL JOURNAL | 1999年 / 319卷 / 7209期
关键词
D O I
10.1136/bmj.319.7209.550
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To compare the effects and tolerability of omeprazole and cisapride with that of placebo for control of heartburn in primary care patients. Design Randomised, double blind, placebo controlled study. Setting 65 primary care practices in Norway. Participants 483 untreated patients with complaints of heartburn greater than or equal to 3 days a week, with at most grade 1 reflux oesophagitis. Interventions Omeprazole 20 mg once daily, cisapride 20 mg twice daily, or placebo for 8 weeks. Main outcome measures Adequate central of heartburn, defined as less than or equal to 1 day of the past 7 days with no more chan mild heartburn after 4 weeks of treatment. Results In the all patients treated analysis, adequate control of heartburn was achieved in 71%, of patients taking omeprazole, 22% taking cisapride, and 18% caking placebo after 4 weeks of treatment (omeprazole v cisapride and placebo, P < 0.0001; cisapride v placebo, non-significant). Results were comparable in patients with or without reflux oesophagitis. In patients treated with omeprazole only, symptom control aas achieved significantly more often in patients positive for Helicobacter pylori. Antacid use was 2-3 times greater in patients taking cisapride or placebo than in those taking omeprazole. Relief of non-reflux symptoms did not significantly differ between the three groups. Significantly more patients ticking cisapride reported adverse events than those taking omeprazole or placebo. Conclusions Omeprazole 20 mg once daily was highly effective in relieving heartburn whereas cisapride 20 mg twice daily was not significantly more effective than placebo.
引用
收藏
页码:550 / 553
页数:4
相关论文
共 24 条
[1]   The endoscopic assessment of esophagitis: A progress report on observer agreement [J].
Armstrong, D ;
Bennett, JR ;
Blum, AL ;
Dent, J ;
deDombal, FT ;
Galmiche, JP ;
Lundell, L ;
Margulies, M ;
Richter, JE ;
Spechler, SJ ;
Tytgat, GNJ ;
Wallin, L .
GASTROENTEROLOGY, 1996, 111 (01) :85-92
[2]  
BOST R, 1992, EUR J GASTROEN HEPAT, V4, P323
[3]   BARRETTS-ESOPHAGUS, THE PREVALENCE OF SHORT AND LONG SEGMENTS IN REFLUX PATIENTS [J].
CAMERON, AJ ;
KAMATH, PS ;
CARPENTER, HC .
GASTROENTEROLOGY, 1995, 108 (04) :A65-A65
[4]   Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole [J].
Carlsson, R ;
Dent, J ;
Watts, R ;
Riley, S ;
Sheikh, R ;
Hatlebakk, J ;
Haug, K ;
de Groot, G ;
van Oudvorst, A ;
Dalvag, A ;
Junghard, O ;
Wiklund, I .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1998, 10 (02) :119-124
[5]  
Castell DO, 1998, AM J GASTROENTEROL, V93, P547
[6]  
CASTELL DO, 1998, PRACT GASTROENTEROL, V22, P18
[7]   CISAPRIDE RESTORES THE DECREASED LOWER ESOPHAGEAL SPHINCTER PRESSURE IN REFLUX PATIENTS [J].
CECCATELLI, P ;
JANSSENS, J ;
VANTRAPPEN, G ;
CUCCHIARA, S .
GUT, 1988, 29 (05) :631-635
[8]  
DEMICCO M, 1992, Gastroenterology, V102, pA59
[9]  
FARUQUI S, 1992, Gastroenterology, V102, pA66
[10]   DOUBLE-BLIND COMPARISON OF CISAPRIDE AND CIMETIDINE IN TREATMENT OF REFLUX ESOPHAGITIS [J].
GALMICHE, JP ;
FRAITAG, B ;
FILOCHE, B ;
EVREUX, M ;
VITAUX, J ;
ZEITOUN, P ;
FOURNET, J ;
SOULE, JC .
DIGESTIVE DISEASES AND SCIENCES, 1990, 35 (05) :649-655